

# Michael Thomas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2160391/publications.pdf>

Version: 2024-02-01

126  
papers

10,325  
citations

101543

36  
h-index

34986

98  
g-index

137  
all docs

137  
docs citations

137  
times ranked

11339  
citing authors

#	ARTICLE	IF	CITATIONS
1	Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 2385-2394.	27.0	3,181
2	Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2014, 370, 1189-1197.	27.0	1,367
3	Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. <i>Lancet</i> , The, 2014, 384, 665-673.	13.7	1,068
4	Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. <i>Lancet Oncology</i> , The, 2012, 13, 247-255.	10.7	549
5	Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3740-3748.	1.6	438
6	Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 959-969.	10.7	222
7	Grading of Tumor Regression in Non-small Cell Lung Cancer. <i>Chest</i> , 2001, 120, 1584-1591.	0.8	152
8	Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians. <i>Translational Lung Cancer Research</i> , 2018, 7, 703-715.	2.8	152
9	Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. <i>Histological assessment. Journal of Cancer Research and Clinical Oncology</i> , 1997, 123, 469-477.	2.5	150
10	Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer. <i>Pneumologie</i> , 2011, 65, 39-59.	0.1	133
11	Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis. <i>International Journal of Cancer</i> , 2019, 144, 848-858.	5.1	131
12	Optimizing panel-based tumor mutational burden (TMB) measurement. <i>Annals of Oncology</i> , 2019, 30, 1496-1506.	1.2	123
13	Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role. <i>British Journal of Cancer</i> , 2014, 111, 1222-1229.	6.4	114
14	AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients. <i>International Journal of Oncology</i> , 2017, 50, 365-372.	3.3	110
15	EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. <i>European Respiratory Journal</i> , 2014, 43, 872-883.	6.7	97
16	EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK non-small cell lung cancer. <i>International Journal of Cancer</i> , 2018, 142, 2589-2598.	5.1	93
17	Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. <i>International Journal of Cancer</i> , 2019, 145, 649-661.	5.1	85
18	Variant classification in precision oncology. <i>International Journal of Cancer</i> , 2019, 145, 2996-3010.	5.1	76

#	ARTICLE	IF	CITATIONS
19	Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, 9008-9008.	1.6	75
20	Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study. Annals of Oncology, 2018, 29, 2076-2084.	1.2	74
21	Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. Journal of Thoracic Oncology, 2019, 14, 1935-1947.	1.1	69
22	Identification of a highly lethal V3<sup>+</sup>TP53<sup>+</sup> subset in ALK<sup>+</sup> lung adenocarcinoma. International Journal of Cancer, 2019, 144, 190-199.	5.1	67
23	Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 407-414.	2.8	64
24	Exercise in Patients with Nonâ€“Small Cell Lung Cancer. Medicine and Science in Sports and Exercise, 2014, 46, 656-663.	0.4	62
25	Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIA non-small-cell lung cancer (NSCLC): the NEOMUN trial. BMC Cancer, 2019, 19, 413.	2.6	57
26	Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9515-9515.	1.6	57
27	Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial. Annals of Oncology, 2017, 28, 1898-1902.	1.2	53
28	Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Lung Cancer, 2021, 152, 174-184.	2.0	53
29	Depression, anxiety and disease-related distress in couples affected by advanced lung cancer. Lung Cancer, 2014, 86, 274-280.	2.0	47
30	Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors. Cancers, 2020, 12, 1046.	3.7	47
31	Glycodelin: A New Biomarker with Immunomodulatory Functions in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2015, 21, 3529-3540.	7.0	45
32	Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience. Lung Cancer, 2021, 153, 150-157.	2.0	45
33	Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients. Scientific Reports, 2016, 6, 33505.	3.3	44
34	MARIPOSA: phase 3 study of first-line amivantamab+â€“azertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. Future Oncology, 2022, 18, 639-647.	2.4	44
35	Symptom Burden and Palliative Care Needs of Patients with Incurable Cancer at Diagnosis and During the Disease Course. Oncologist, 2021, 26, e1058-e1065.	3.7	42
36	Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. Lung Cancer, 2016, 93, 95-103.	2.0	41

#	ARTICLE	IF	CITATIONS
37	A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3- $\beta$ -D-glucan; Imprime PGC) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer. <i>Investigational New Drugs</i> , 2017, 35, 345-358.	2.6	40
38	Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. <i>Lung Cancer</i> , 2017, 112, 181-187.	2.0	40
39	A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma. <i>OncoImmunology</i> , 2021, 10, 1860586.	4.6	40
40	Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival. <i>Cancers</i> , 2019, 11, 124.	3.7	36
41	Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. <i>ESMO Open</i> , 2021, 6, 100254.	4.5	35
42	Defining molecular risk in ALK+ NSCLC. <i>Oncotarget</i> , 2019, 10, 3093-3103.	1.8	35
43	Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas. <i>European Journal of Medical Research</i> , 2015, 20, 64.	2.2	34
44	Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study. <i>Current Medical Research and Opinion</i> , 2014, 30, 447-461.	1.9	33
45	Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 703893.	2.8	33
46	Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA. <i>EBioMedicine</i> , 2020, 62, 103103.	6.1	32
47	Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement. <i>Lung Cancer</i> , 2020, 142, 114-119.	2.0	28
48	EML4-ALK V3, treatment resistance, and survival: refining the diagnosis of ALK+ NSCLC. <i>Journal of Thoracic Disease</i> , 2018, 10, S1989-S1991.	1.4	26
49	Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing. <i>Lung Cancer</i> , 2020, 148, 105-112.	2.0	26
50	The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC. <i>Frontiers in Oncology</i> , 2019, 9, 1550.	2.8	26
51	Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199650.	3.2	24
52	POSITIVE study: physical exercise program in non-operable lung cancer patients undergoing palliative treatment. <i>BMC Cancer</i> , 2016, 16, 499.	2.6	23
53	Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 251-265.	4.2	22
54	Psychometric evaluation of the German Version of the Supportive Care Needs Survey for Partners and Caregivers (SCNS-P&C-G) of cancer patients. <i>European Journal of Cancer Care</i> , 2015, 24, 884-897.	1.5	21

#	ARTICLE	IF	CITATIONS
55	Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance. <i>Lung Cancer</i> , 2018, 119, 48-55.	2.0	21
56	Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis. <i>Npj Precision Oncology</i> , 2021, 5, 100.	5.4	21
57	Symptoms and Needs of Patients with Advanced Lung Cancer: Early Prevalence Assessment. <i>Oncology Research and Treatment</i> , 2019, 42, 650-659.	1.2	20
58	A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy. <i>Npj Precision Oncology</i> , 2022, 6, 19.	5.4	20
59	The Heidelberg Milestones Communication Approach (MCA) for patients with prognosis &lt;12 months: protocol for a mixed-methods study including a randomized controlled trial. <i>Trials</i> , 2018, 19, 438.	1.6	18
60	A longitudinal communication approach in advanced lung cancer: A qualitative study of patientsâ€™, relativesâ€™ and staff's perspectives. <i>European Journal of Cancer Care</i> , 2018, 27, e12794.	1.5	17
61	Erlotinib. <i>Recent Results in Cancer Research</i> , 2018, 211, 1-17.	1.8	17
62	The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma. <i>ESMO Open</i> , 2021, 6, 100253.	4.5	17
63	Earlier extracranial progression and shorter survival in ALK- rearranged lung cancer with positive liquid rebiopsies. <i>Translational Lung Cancer Research</i> , 2021, 10, 2118-2131.	2.8	16
64	Physical Performance and Psychosocial Status in Lung Cancer Patients: Results from a Pilot Study. <i>Oncology Research and Treatment</i> , 2014, 37, 36-41.	1.2	15
65	Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancerâ€™ Cross-Sectional Study of Eligibility and Administration Rates. <i>Frontiers in Oncology</i> , 2020, 10, 586449.	2.8	15
66	The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions. <i>European Journal of Cancer</i> , 2022, 170, 106-118.	2.8	15
67	Erlotinib and bevacizumab <i>versus</i> cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2015, 46, 219-229.	6.7	14
68	A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer. <i>Investigational New Drugs</i> , 2020, 38, 1145-1155.	2.6	14
69	Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa038.	0.7	14
70	Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma. <i>Oncotarget</i> , 2016, 7, 71285-71297.	1.8	13
71	Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in <i>KLC1â€™ALK</i>-rearranged lung cancer. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a004630.	1.2	13
72	TP53 co-mutations as an independent prognostic factor in 2nd and further line therapyâ€™EGFR mutated non-small cell lung cancer IV patients treated with osimertinib. <i>Translational Lung Cancer Research</i> , 2022, 11, 4-13.	2.8	13

#	ARTICLE	IF	CITATIONS
73	Paclitaxel for treatment of advanced small cell lung cancer (SCLC): a retrospective study of 185 patients. <i>Journal of Thoracic Disease</i> , 2020, 12, 782-793.	1.4	12
74	Glycodelin as a Serum and Tissue Biomarker for Metastatic and Advanced NSCLC. <i>Cancers</i> , 2018, 10, 486.	3.7	11
75	Safety and Efficacy of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors Using a Risk-optimized Fractionation Scheme. <i>Clinical Lung Cancer</i> , 2020, 22, 332-340.e3.	2.6	11
76	Ion therapy within the trimodal management of superior sulcus tumors: the INKA trial. <i>BMC Cancer</i> , 2015, 15, 192.	2.6	10
77	Implementation of the milestones communication approach for patients with limited prognosis: evaluation of intervention fidelity. <i>BMC Palliative Care</i> , 2020, 19, 21.	1.8	10
78	A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol. <i>Clinical Lung Cancer</i> , 2021, 22, 142-146.	2.6	10
79	Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 670483.	2.8	10
80	Interferon Regulatory Factor 9 Promotes Lung Cancer Progression via Regulation of Versican. <i>Cancers</i> , 2021, 13, 208.	3.7	10
81	Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives. <i>Translational Lung Cancer Research</i> , 2020, 9, 1000-1014.	2.8	9
82	Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor Cobiciclat. <i>Clinical and Translational Science</i> , 2021, 14, 487-491.	3.1	9
83	Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer. <i>ESMO Open</i> , 2021, 6, 100161.	4.5	9
84	Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field. <i>Lung Cancer</i> , 2021, 154, 131-141.	2.0	8
85	Effects of an Interprofessional Communication Approach on Support Needs, Quality of Life, and Mood of Patients with Advanced Lung Cancer: A Randomized Trial. <i>Oncologist</i> , 2021, 26, e1445-e1459.	3.7	8
86	Genome-Wide DNA Methylation Profiling in Early Stage I Lung Adenocarcinoma Reveals Predictive Aberrant Methylation in the Promoter Region of the Long Noncoding RNA PLUT: An Exploratory Study. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1338-1350.	1.1	8
87	Exercise behavior and physical fitness in patients with advanced lung cancer. <i>Supportive Care in Cancer</i> , 2018, 26, 2725-2736.	2.2	7
88	Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy. <i>ESMO Open</i> , 2020, 5, e000567.	4.5	7
89	Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial. <i>Trials</i> , 2020, 21, 352.	1.6	7
90	CANOPY-A: A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS9075-TPS9075.	1.6	6

#	ARTICLE	IF	CITATIONS
91	Comparison of two ERCC1 antibodies as prognostic and predictive biomarkers for early non-small cell lung cancer. <i>Anticancer Research</i> , 2014, 34, 3707-13.	1.1	6
92	Deficient CD247 expression is a typical histopathological characteristic of thymomas with cortical features. <i>Histopathology</i> , 2018, 73, 1040-1043.	2.9	5
93	ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer. <i>Medical Oncology</i> , 2018, 35, 106.	2.5	5
94	Histological and Molecular Plasticity of ALK-positive Non-Small-Cell Lung Cancer under Targeted Therapy - a Case Report. <i>Journal of Physical Education and Sports Management</i> , 2022, , mcs.a006156.	1.2	5
95	Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib. <i>Cancers</i> , 2022, 14, 2720.	3.7	5
96	De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 640048.	2.8	4
97	Evaluation of TMB estimates for the prediction of response to immune checkpoint blockage.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2632-2632.	1.6	4
98	Impact of EMT in stage I/II NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab. <i>Oncology Letters</i> , 2019, 17, 4891-4900.	1.8	3
99	Novel Liquid Biomarker Panels for A Very Early Response Capturing of NSCLC Therapies in Advanced Stages. <i>Cancers</i> , 2020, 12, 954.	3.7	3
100	Lung cancer patients' comorbidities and attendance of German ambulatory physicians in a 5-year cross-sectional study. <i>Npj Primary Care Respiratory Medicine</i> , 2021, 31, 2.	2.6	3
101	Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial. <i>BMC Cancer</i> , 2021, 21, 743.	2.6	3
102	Endogenous anti-Î²-glucan antibodies as a potential predictive biomarker for clinical response to imprime PGG immunotherapy in non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3045-3045.	1.6	3
103	Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery. <i>Lung Cancer</i> , 2022, 164, 46-51.	2.0	3
104	Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA. <i>Cancers</i> , 2022, 14, 2479.	3.7	3
105	Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Stage NSCLC With High Programmed Death-Ligand 1 Expression. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100369.	1.1	3
106	Phase I study of lapatinib, a dual-tyrosine kinase inhibitor, and pemetrexed in the second-line treatment of advanced or metastatic non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, e19027-e19027.	1.6	2
107	Impact of molecular alterations on quality of life and prognostic understanding over time in patients with incurable lung cancer: a multicenter, longitudinal, prospective cohort study. <i>Supportive Care in Cancer</i> , 2022, 30, 3131-3140.	2.2	2
108	Germline Genetic Variants of the Renin-Angiotensin System, Hypoxia and Angiogenesis in Non-Small Cell Lung Cancer Progression: Discovery and Validation Studies. <i>Cancers</i> , 2020, 12, 3834.	3.7	1

#	ARTICLE	IF	CITATIONS
109	Validation of the T Descriptor (TNM-8) in T3N0 Non-Small-Cell Lung Cancer Patients; a Bicentric Cohort Analysis with Arguments for Redefinition. <i>Cancers</i> , 2021, 13, 1812.	3.7	1
110	A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199650.	3.2	1
111	Disease monitoring and TKI resistance mutations of EGFR mutation-positive NSCLC patients via circulating tumor DNA.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21627-e21627.	1.6	1
112	Abstract 3374: Large-scale single-cell whole transcriptomic analyses reveal distinct malignant phenotypes of CTCs from NSCLC patients. <i>Cancer Research</i> , 2022, 82, 3374-3374.	0.9	1
113	Mesenchymal Stromal Cells Derived from Human Non-Small Cell Lung Cancer, Normal Lung Tissue, and Bone Marrow: Differences in Frequency, Cytogenetics, Proliferation Behavior, and Chemosensitivity - Implications for Cancer Therapy.. <i>Blood</i> , 2007, 110, 1925-1925.	1.4	0
114	TP53 status conversion defines an unfavourable patient subset with inferior overall survival in ALK+ lung adenocarcinoma. , 2019, 73, .		0
115	A framework for risk stratification in EGFR+ lung adenocarcinoma treated with tyrosine kinase inhibitors. , 2019, 73, .		0
116	Konzeptentwicklung und -Anpassung für eine komplexe Intervention: Heidelberger Meilenstein-Kommunikation (HeiMeKOM) am Beispiel Lungenkrebspatienten mit Prognose <math>\leq 12</math> Monate. <i>Pneumologie</i> , 2019, 73, .	0.1	0
117	Frequency and clinical impact of atypical EGFR mutations in lung adenocarcinoma. , 2019, 73, .		0
118	Clinical predictors of immune checkpoint inhibitor efficacy in non-small cell lung cancer. , 2019, 73, .		0
119	Totality of evidence in development of the bevacizumab biosimilar ABP 215: Central and investigator evaluation of efficacy from the MAPLE study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20708-e20708.	1.6	0
120	Early assessment of therapy response in non-small cell lung cancer (NSCLC) via longitudinal ctDNA analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20701-e20701.	1.6	0
121	Assessing the impact of clonal hematopoiesis in disease monitoring using targeted cell-free DNA (cfDNA) sequencing technology.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14530-e14530.	1.6	0
122	Bronchoskopische Rebiopsie bei Patienten mit Lungenkarzinom. , 2020, 74, .		0
123	Clinical and molecular profile of de novo vs. secondary EGFR mutated metastatic non-small-cell lung cancer. <i>Pneumologie</i> , 2020, 74, .	0.1	0
124	Heidelberger Meilenstein Kommunikation (HeiMeKOM), ein interprofessionelles Kommunikationskonzept für Patient:innen mit Lungenkrebs und eingeschränkter Prognose: Ergebnisse einer mixed-methods Studie. <i>Pneumologie</i> , 2022, . .	0.1	0
125	Die seltene thorakale Manifestation eines extramedullären Myeloms. <i>Pneumologie</i> , 2022, . .	0.1	0
126	Wenn Lungenkrebs die Lebensplanung erschwert: Studie zur Erfassung der individuellen Werte von Lungenkrebspatient:innen mit der Human Values Scale. <i>Pneumologie</i> , 2022, . .	0.1	0